<SEC-DOCUMENT>0001193125-18-280561.txt : 20180924
<SEC-HEADER>0001193125-18-280561.hdr.sgml : 20180924
<ACCEPTANCE-DATETIME>20180924075357
ACCESSION NUMBER:		0001193125-18-280561
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180924
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180924
DATE AS OF CHANGE:		20180924

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		181082630

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d629023d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): September&nbsp;24, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">0-21392</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street <FONT STYLE="white-space:nowrap">28-32,</FONT> Dublin
2,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ireland</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act
(17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or
Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (17 CFR <FONT STYLE="white-space:nowrap">&#167;240.12b-2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2018, Amarin Corporation plc issued a press release titled, <FONT STYLE="white-space:nowrap">&#147;REDUCE-IT&#153;</FONT>
Cardiovascular Outcomes Study of Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) Capsules Met Primary Endpoint&#148; (the &#147;Press Release&#148;). A copy of the Press Release is attached hereto as Exhibit 99.1
and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;No.&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d629023dex991.htm">Press Release, dated September&nbsp;24, 2018 </A></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: September&nbsp;24, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">AMARIN CORPORATION PLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Thero</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John Thero</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d629023dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 99.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g629023g0924152933272.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">REDUCE-IT&#153;</FONT> Cardiovascular Outcomes Study of Vascepa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) Capsules </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Met Primary Endpoint </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Is First Outcomes Study to Assess Treatment of Patients with <FONT
STYLE="white-space:nowrap">LDL-C</FONT> Controlled by Statin Therapy, Persistent Elevated Triglycerides and Other Cardiovascular Risk Factors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Results Specific to Pure EPA Vascepa at 4 Grams Daily </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Conference Call Scheduled for Today, Monday, September&nbsp;24, 2018 at 8:00 am ET </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BEDMINSTER, NJ</B><B></B><B>&nbsp;and</B><B></B><B>&nbsp;DUBLIN, IRELAND</B>&nbsp;September 24, 2018 - Amarin Corporation plc&nbsp;(NASDAQ:AMRN), announced
today topline results from the Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> cardiovascular (CV)&nbsp;outcomes trial, <FONT STYLE="white-space:nowrap">REDUCE-IT&#153;,</FONT> a global study of 8,179 statin-treated adults with
elevated CV risk. <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> met its primary endpoint demonstrating an approximately 25% relative risk reduction, to a high degree of statistical significance (p&lt;0.001), in major adverse CV events (MACE) in
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> patient population with use of Vascepa 4 grams/day as compared to placebo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients enrolled in <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> had <FONT STYLE="white-space:nowrap">LDL-C</FONT> between <FONT
STYLE="white-space:nowrap">41-100</FONT> mg/dL (median baseline <FONT STYLE="white-space:nowrap">LDL-C</FONT> 75 mg/dL) controlled by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides (TGs) between <FONT
STYLE="white-space:nowrap">150-499</FONT> mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other CV risk factor (primary prevention cohort). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key topline results include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Efficacy:</U> Approximately 25% relative risk reduction, demonstrated to a high degree of statistical
significance (p&lt;0.001), in the primary endpoint composite of the first occurrence of MACE, including cardiovascular death, nonfatal myocardial infarction (MI), nonfatal stroke, coronary revascularization, or unstable angina requiring
hospitalization. This result was supported by robust demonstrations of efficacy across multiple secondary endpoints. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Safety:</U> Vascepa was well tolerated with a safety profile consistent with clinical experience associated
with <FONT STYLE="white-space:nowrap">omega-3</FONT> fatty acids and current <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling. The proportions of patients experiencing adverse events and serious adverse events in <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> were similar between the active and placebo treatment groups. Median <FONT STYLE="white-space:nowrap">follow-up</FONT> time in <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> was 4.9 years.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin is eager to share <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> data in greater detail with both the medical community and
regulatory authorities. <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results have been accepted for presentation at the 2018 Scientific Sessions of the American Heart Association (AHA) on November&nbsp;10, 2018 in Chicago, Illinois. The
presentation, classified as late breaking clinical trial results, is scheduled to commence at 2:16 pm Central Time and listed as Main Event 1 for the time frame. This acceptance as a presentation of late-breaking clinical trial results was granted
based on the ability of <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> to address a critical question in cardiovascular prevention. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I look forward to the publication of these detailed <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
results in a major peer-reviewed journal and to presenting them at the AHA in November,&#148; stated Deepak L. Bhatt, MD, MPH, Professor of Medicine at Harvard Medical School, Executive Director of Interventional Cardiovascular Programs in the Heart
and Vascular Center at Brigham and Women&#146;s Hospital, and the Principal Investigator and Steering Committee Chair for <FONT STYLE="white-space:nowrap">REDUCE-IT.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Amarin expresses its great appreciation for all the people that brought <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> to completion, especially the
patients and investigators and their colleagues at clinical sites that participated in this study for many years,&#148; stated Steven Ketchum, PhD, president of research and development and chief scientific officer of Amarin. &#147;Amarin is also
grateful to the U.S. Food and Drug Administration (FDA) for its continued encouragement and support toward study design and completion. <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> was conducted under a special protocol assessment agreement
with FDA that was <FONT STYLE="white-space:nowrap">re-affirmed</FONT> in 2016.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted with these topline study results,&#148; said
John F. Thero, president and CEO of Amarin. &#147;Given Vascepa is affordably priced, orally administered and has a favorable safety profile, <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results could lead to a new paradigm in treatment to
further reduce the significant cardiovascular risk that remains in millions of patients with <FONT STYLE="white-space:nowrap">LDL-C</FONT> controlled by statin therapy, as studied in <FONT STYLE="white-space:nowrap">REDUCE-IT.&#148;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Considered against the backdrop of multiple unsuccessful cardiovascular outcomes studies of earlier generation drug therapies, including multiple recent
failed cardiovascular studies of <FONT STYLE="white-space:nowrap">omega-3</FONT> mixture products that contain the <FONT STYLE="white-space:nowrap">omega-3</FONT> acid DHA, <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> topline results stand
alone as positive and confirm our hypothesis that pure EPA Vascepa at 4 grams/day can provide additional cardiovascular risk reduction benefit on top of <FONT STYLE="white-space:nowrap">LDL-C</FONT> control with standard of care statin therapy in
studied patients,&#148; added Craig Granowitz, MD, PhD, senior vice president and chief medical officer of Amarin. <FONT STYLE="white-space:nowrap">&#147;REDUCE-IT</FONT> results cannot be generalized to fenofibrate, fish oil or <FONT
STYLE="white-space:nowrap">omega-3</FONT> mixture products that contain DHA. The most relevant comparator study to <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> is the Japan EPA lipid intervention study (JELIS), the 18,645 patient, open label,
blinded endpoint outcomes study of EPA added to <FONT STYLE="white-space:nowrap">low-dose</FONT> statin therapy, which showed cardiovascular event reduction in Japanese hypercholesterolemic patients of 19% in the overall population and 53% in a
subgroup of patients with elevated TG levels and low <FONT STYLE="white-space:nowrap">HDL-C.&#148;</FONT><SUP STYLE="font-size:85%; vertical-align:top">1, 2, 3</SUP> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial Expansion and Next Steps </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously
described, given the successful topline results of <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> Amarin is in the process of increasing the number of company sales representatives promoting Vascepa to over 400 people in the United States. This
will provide a greater concentration of coverage in current sales territories and provide new coverage where Amarin currently does not have sales representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to sales force expansion in the United States, Amarin plans to work with its international partners to support regulatory efforts outside the
United States based on <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results. As previously described in the months leading up to <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results, Amarin increased its Vascepa inventory levels in
preparation for positive results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall managed care insurance coverage for Vascepa has been broad. Amarin looks forward to working with
insurance carriers to increase understanding of <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results and the potential benefits Vascepa could bring to many millions of patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Study Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study commenced in 2011, enrolled and followed 8,179 randomized patients, and was
conducted based on a special protocol assessment agreement with FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> is the first global cardiovascular
outcomes study to prospectively evaluate the effect of Vascepa, or any therapy, in adult patients with <FONT STYLE="white-space:nowrap">LDL-C</FONT> controlled to between <FONT STYLE="white-space:nowrap">41-100</FONT> mg/dL (median baseline 75
mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated TGs between <FONT STYLE="white-space:nowrap">150-499</FONT> mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary
prevention cohort) or diabetes mellitus and at least one other CV risk factor (primary prevention cohort). The design of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study was published in March 2017 in <I>Clinical
Cardiology</I><SUP STYLE="font-size:85%; vertical-align:top">4</SUP> and can be found in the R&amp;D section on the company&#146;s website at <U>www.amarincorp.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> hypothesis tested whether additional cardiovascular risk reduction beyond
<FONT STYLE="white-space:nowrap">LDL-C</FONT> controlled with statin therapy could be achieved in high risk patients with the putative cardioprotective effects of Vascepa 4 grams/day. Independent of <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT>
Amarin has worked to further support the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> hypothesis with published scientific findings based on various degrees of evidence that show EPA may interrupt the atherosclerotic process (e.g., plaque
formation and instability) by beneficially affecting cellular functions thought to contribute to atherosclerosis and cardiovascular events and by beneficially affecting lipid, lipoprotein and inflammation biomarkers.<SUP
STYLE="font-size:85%; vertical-align:top">5, 6, 7, 8, 9</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Disclosure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Funding from Amarin was provided to Brigham and Women&#146;s Hospital for Dr.&nbsp;Deepak&nbsp;L. Bhatt&#146;s work as the
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study chair and international principal investigator. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call and Webcast Information
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin&nbsp;will host<B> </B>a conference call at&nbsp;8:00 a.m. ET,&nbsp;September 24, 2018 to discuss this information. The call will be accessible
through the investor relations section of the company&#146;s website at <U>www.amarincorp.com</U>. The call can also be heard via telephone by dialing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">877-407-8033.</FONT></FONT> A
replay of the call will be made available for a period of two weeks following the conference call. To hear a replay of the call, dial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">877-481-4010</FONT></FONT> (inside the United
States) or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">919-882-2331</FONT></FONT> (outside the United States). A replay of the call will also be available through the company&#146;s website shortly after the call. For both <FONT
STYLE="white-space:nowrap">dial-in</FONT> numbers please use conference ID 37638. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health.
Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa (icosapent ethyl) is Amarin&#146;s first
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug and is available by prescription in the United States, Lebanon and the United Arab Emirates. Amarin&#146;s commercial partners are pursuing additional regulatory approvals for Vascepa in
Canada, China and the Middle East. For more information about Amarin, visit <U>www.amarincorp.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cardiovascular Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Worldwide, cardiovascular disease (CVD) remains the #1 killer of men and women. In the United States CVD leads to one in every three deaths &#150; one death
approximately every 38 seconds &#150; with annual treatment cost in excess of $500&nbsp;billion.<SUP STYLE="font-size:85%; vertical-align:top">10, 11</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Multiple&nbsp;primary and secondary prevention trials have shown a significant reduction of 25% to 35% in the risk of cardiovascular events with statin
therapy, leaving significant persistent residual risk despite the achievement of target <FONT STYLE="white-space:nowrap">LDL-C</FONT> levels.<SUP STYLE="font-size:85%; vertical-align:top">5</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond the cardiovascular risk associated with <FONT STYLE="white-space:nowrap">LDL-C,</FONT> genetic, epidemiologic, clinical and real-world data suggest
that patients with elevated triglycerides (TG) (fats in the blood), and <FONT STYLE="white-space:nowrap">TG-rich</FONT> lipoproteins, are at increased risk for cardiovascular disease.<SUP STYLE="font-size:85%; vertical-align:top"> 12, 13, 14,
15</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent ethyl) Capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules are a single-molecule prescription product consisting of the <FONT
STYLE="white-space:nowrap">omega-3</FONT> acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> manufacturing process
designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient. Vascepa, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple
patents internationally based on the unique clinical profile of Vascepa, including the drug&#146;s ability to lower triglyceride levels in relevant patient populations without raising <FONT STYLE="white-space:nowrap">LDL-cholesterol</FONT> levels.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Indication and Usage Based on Current <FONT STYLE="white-space:nowrap">FDA-Approved</FONT> Label (not including
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results) </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients
with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with
severe hypertriglyceridemia has not been determined. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for Vascepa Based on Current <FONT
STYLE="white-space:nowrap">FDA-Approved</FONT> Label (not including <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results) (Includes Data from Two <FONT STYLE="white-space:nowrap">12-Week</FONT> Studies (n=622) (MARINE and ANCHOR) of Patients
with Triglycerides Values of 200 to 2000 mg/dL) </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or
any of its components. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use with caution in patients with known hypersensitivity to fish and/or shellfish. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The most common reported adverse reaction (incidence &gt;2% and greater than placebo) was arthralgia (2.3% for
Vascepa, 1.0% for placebo). There was no reported adverse reaction &gt;3% and greater than placebo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adverse events and product complaints may be reported by calling <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-855-VASCEPA</FONT></FONT> or the FDA at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-FDA-1088.</FONT></FONT></FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients receiving treatment with Vascepa and other drugs affecting coagulation (e.g., anti-platelet agents)
should be monitored periodically. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients should be advised to swallow Vascepa capsules whole; not to break open, crush, dissolve, or chew
Vascepa. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa has been approved for use by the United States Food and Drug Administration (FDA) as an adjunct to diet to reduce triglyceride levels in adult
patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. Nothing in this press release should be construed as promoting the use of Vascepa in any indication that has not been approved by the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Cautionary Information About Topline Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Existing and prospective investors are cautioned not to place undue reliance on topline results. As with any topline cardiovascular outcomes study result,
further <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> data assessment and data release will yield additional useful information to inform greater understanding of the study outcome. Aspects that could change and impact the final evaluation of
the totality of the efficacy/safety data from <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> may include: the magnitude of the treatment benefit on the primary composite endpoint, its components, secondary endpoints and the primary and secondary
risk prevention cohorts; consideration of which components of the composite or secondary endpoints have the most clinical significance; the consistency of the primary and secondary endpoints; the consistency of findings across cohorts and subgroups;
tolerability and safety considerations and risk/benefit considerations; consideration of <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results in the context of other clinical studies; and study conduct and data quality, integrity and
consistency. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press
release contains forward-looking statements, including expectations regarding planned publication, scientific presentation, regulatory review and related timing thereof; expectations that <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results
could lead to a new treatment paradigm in the patient population studied; plans for sales force, international and insurance coverage expansion. These forward-looking statements are not promises or guarantees and involve substantial risks and
uncertainties. In addition, Amarin&#146;s ability to effectively commercialize Vascepa will depend in part on its ability to continue to effectively finance its business, efforts of third parties, its ability to create market demand for Vascepa
through education, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing and sales activities, to achieve market acceptance of Vascepa, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of
commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepa. Among the factors that could cause actual results to
differ materially from those described or projected herein include the following: uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that sales may not meet expectations and
related cost may increase beyond expectations; the risk that patents may not be upheld in patent litigation and applications may not result in issued patents sufficient to protect the Vascepa franchise. A further list and description of these risks,
uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent quarterly report on Form
<FONT STYLE="white-space:nowrap">10-Q.</FONT> Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or
revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Other Information About Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors
and others should note that Amarin communicates with its investors and the public using the company website <U>http://www.amarincorp.com/</U>), the investor relations website (<U>http://investor.amarincorp.com/</U>), including but not limited to
investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information.
As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from
time to time on Amarin&#146;s investor relations website and may include social media channels. The contents of Amarin&#146;s website or these channels, or any other website that may be accessed from its website or these channels, shall not be
deemed incorporated by reference in any filing under the Securities Act of 1933. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>References </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in
hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. <I>Lancet</I>. 2007;369(9567):1090-1098. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic
patients with multiple risk factors: <FONT STYLE="white-space:nowrap">sub-analysis</FONT> of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). <I>Atherosclerosis</I>.
<FONT STYLE="white-space:nowrap">2008;200(1):135-140.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Matsuzaki M, Yokoyama M, Saito Y, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events
in statin-treated patients with coronary artery disease. <I>Circ J. </I>2009;73(7):1283-1290. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bhatt DL, Steg G, Brinton EA, et al. Rationale and design of <FONT STYLE="white-space:nowrap">REDUCE-IT:</FONT>
Reduction of Cardiovascular Events with Icosapent Ethyl&#150;Intervention Trial. <I>Clinical Cardiology</I>. <FONT STYLE="white-space:nowrap">2017;40:138-148.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia
management. <I>J Am Coll Cardiol</I>. <FONT STYLE="white-space:nowrap">2018;72(3):330-343.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of
eicosapentaenoic acid (EPA) in atherosclerosis. <I>Atherosclerosis</I>. <FONT STYLE="white-space:nowrap">2015;242(1):357-366.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nelson JR, Wani O, May HT, et al. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques.
<I>Vascul Pharmacol</I>. 2017;91:1&#150;9. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mason RP, Dawoud H, Jacob RF, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide
bioavailability in a manner that is enhanced in combination with a statin. <I>Biomed Pharmacother</I>. 2018;103:1231-1237. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">9</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Takamura M, Kurokawa K, Ootsuji H, et al. Long-term administration of eicosapentaenoic acid improves
post-myocardial infarction cardiac remodeling in mice by regulating macrophage polarization. <I>J Am Heart Assoc</I>. 2017;6(2). pii: e004560. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">10</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Heart Association. 2018. Disease and Stroke Statistics-2018 Update. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">11</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Heart Association. 2017. Cardiovascular disease: A costly burden for America projections through 2035.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">12</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease.
<I>Am J Cardiol</I>. <FONT STYLE="white-space:nowrap">2016;118:138-145.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">13</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events,
medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. <I>J Am Heart Assoc.</I> 2018;7(15):e008740. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">14</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from
epidemiology, genetics, and biology. <I>Circ Res</I>. <FONT STYLE="white-space:nowrap">2016;118:547-563.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">15</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. <I>Lancet.</I> 2014;384:626&#150;635.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Relations: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabeth Schwartz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin
Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (908) <FONT STYLE="white-space:nowrap">719-1315</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee M. Stern </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trout Group</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (646)
<FONT STYLE="white-space:nowrap">378-2992</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lstern@troutgroup.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Inquiries: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christy Maginn </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Burson-Marsteller </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (646) <FONT
STYLE="white-space:nowrap">280-5210</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Christy.Maginn@bm.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g629023g0924152933272.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g629023g0924152933272.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] 2\# 2(  A$! Q$!_\0
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MPZ$$9!J6N,Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HK!U76]4L+WR+3PW>ZA%L#>?%-$J
MY],,P/%9S>*O$ ) \#:F?^WJ#_XJJ46Q71U]<UX\\2+X7\)W=^&'VAAY5NI[
MR-P/RZ_A5,^+/$@''@/43_V]P_XUYWK>KZOX\\;V=J/#MR]OHS>9<Z>)TW%\
M]VSM]!CZU<(7=WL3*6FAKP?#9KGX2?9Y$SK4Q_M .WWC(1PI/NO'U->($$$A
M@00<$'J#7U&/$?B$C_D2KT?6\@_^*KQ;XH^&Y-'U^/4EMFM[?4U\XQ$@^5+_
M !ID<>_YUT49OF:?4RJ15KH[SX+>*?MNE2^'[F3,]G\]OD\M$3R/P/\ .O5Z
M^1O#NMW'AW7[/5+<G= ^67^^IX9?Q%?6%A?0:EI]O>VKAX)XQ(C#N"*QQ$.6
M5UU+I2NK%FO.?%/B?QWX:@NK]M'T>;38G.)$E<N$SP6&1^.*]&KDOB8,_#S6
M/^N)-9PMS),N6QYC_P +UU__ *!6F_G)_C7JW@;Q4OB_PY'J#(D5RK&.>)#P
MK#TSV(KY\\1^'#INAZ%J\*$6]_;?.1T$H)_F/Y5O?"'Q+_8WBG^SYY-MKJ V
M<G@2#[I_I^-=-2E%PO%&,9R4K2/HJF2R)#$\LC!412S$]@*?7!_$_5YX='M]
M"L"3J&KR"WC"]0A^\:Y8QYG8W;LKG$7_ ,<]5CU"X2QTRP>U60K$\A?<RCN<
M&M/PU\2?&OBRZEM]*T72&:%=TC2R.JJ.W>O,?&FDPZ%XHN-,MU 2W2->.YV\
MG\37?_ ?_D(ZQ_UR3^==<X05/F2,(RDY6;/9=.:];3X6U%(4O"O[U8"2@;V)
MYQ5DD $DX ZDTM<[XYU:TT?P?J%Q>*'1HC&L9.-[-P!7&E=V-WHCD/$OQ@LM
M,\16MAIHCNK:.7;>S]0!TPA[D>M>FP3QW,$<\+AXY%#*P[@U\>7=E<V$_D7<
M#P2[0^QQV(R*]R^#7BO[?I;Z#=29N+0;H2QY:/T_"NFK148WB90J-NS/5:Q]
M>E\00PQ-H%K87$FX^:MW*R#';! /-;%%<R-CQ/5/C+XBTC4;C3[S0K".Y@;:
MZB9F /U%7?#?Q%\;>+YKB+2-+T4-;@,XF>0<'TYKSKXD#'Q"UC_KM_2NT^!'
M_(3U?C_EDG\S79*$%3YDCG4I.5KFWJ_C;XA>&H?M.K>&-/DM%/S36TC%5^I!
M./Q%6O#WQHT359TMM3@DTR9R KNP>(G_ 'NWXBO2)H8YX7AE0/&ZE65AP0>H
MKY$UVUBLM>U"UAQY,5PZ)] :SI1A4NFK%3<H:W/KQ75T#HP92,@@Y!KAO%>O
M>-M!6]O[32](N-*M_F#-*_F[?4C@?E6?\%=3NKWPE-;W#LZVDYCB9CG"X!Q^
M&:ZCQ[_R(FL_]>S5ER\L^5EWO&YY/_PO77_^@5IOYR?XUV.A^)?B-K^F1ZA:
MZ'HD5O*-T1GFD4N/4 $\?6OGO^'\*^JO '_(A:+_ ->J?RK>M&,%=(SIR<GJ
MSA_$GQ"\=>$_).K:#I*1S$B.2*5W4D=1UX-8 ^.NO9&=)TTCN 9/\:Z3XX -
MI^A*0"#>$$'N.*XSXC?#N3PVXU;3(V?29<%E')MV/8_[)['\**:IM+F6X2<D
MW9GMWA7Q38>+-'2_LFPWW9H6/S1/W!_Q[UN5\F>%O%%_X3UA-0L6W*?EF@)^
M65/0^_H>U?3OAWQ#8>)M'AU'3Y-T;\,I^]&W=6'8BLJM)P=UL7"?,CEO$OB'
MQWH,%W>Q:%I=S80,Q#QSNT@C'\3+QVZXK&\+^/O''B\R/IFAZ2+>%@LLTTKJ
MH/H.<DXKTW5,?V1>Y (\A^#_ +IK@_@F,>  ?6[E/\J$UR-V!I\UKFWK7BJY
MMK][+3X8?W+I%-<31R2#S67<(T2,%F;;R3P ,5=\.>(CK&^"XCB2X6))T>!R
MT4\3YVR(2 >H(((R"*PO$&@SB_N!)97=YI5U=K>M]B(\Z.41F,J064[2,$,#
MD$$8Q6AX3TB]@F6^OH?L_E6<=C;0L%#^6I)+N%)568D?*"<8]ZEJ/*--W,[Q
M?;V,VLAKBT\6R.L2C=I)D$..?[I W>OX5SS6FD#_ )<_B*/HTO\ C70>,=0L
M+36E2Z\7ZOI+F%2+>TMRZ8R?FSY;<GZ]JYMM<TD'_DIGB ?6R/\ \:JXWM_P
MY,K7,[6[K1M,TJ>XV>/;>4*5B:ZFDCC+D?*"Q/K5+PEH]M!I0N=4T?QC)?7+
M&1Y[!71'4\KR&!;UR?6LWQ!J4&N>(+/2Y/%6JZEHT9$LUQ+;DE&Y^ZBKD\8&
M2.IKKH]8TI=H'Q"\4 #M]B./_15:NZC8A6;-;2M.TRXO[>%+'QU 6< 27,TR
MQKW^8[^E=3XZ\-)XI\+75A@"X4>9;M_=D'3\^GXUF^"YK:_OIY[3Q5K&JK"F
MUX;V'RT&[H>44D\'O7;USRDU+T-4DT?&CQO%(\4B%)$8JZD<J1P17M?P3\4^
M=;3^'+F3YX<RVN3U7^)?P//XFN:^,7A@Z1XD75K>+%IJ'+D#A91U_,<_G7#:
M+JUQH6LVFIVK8EMY X']X=P?8BNV256GH8*\)'U]7*_$@9^'NLC_ *=VK=TG
M4[?6-*M=1M6W0W$8=?;/;Z@\5@?$M]GP\UDYQF BN"/Q(Z)?"8-OX=3Q-\%;
M&QP//%KYD!]'!)%?/ZM+;3AANCFB?Z%6!_QKZD^'O_(@:+_U[C^9KQ7XL^&_
M[#\6M=PIBUU &5<#@/\ Q#^M=5&?O.+,JD?=3/;?!?B./Q)X3M=29QYH39<#
M/W77K_C^-<KX54^,/B#J/B>4%K'3R;2QST)_B8?Y]*\F\+^*-3TFPU'1;!6=
MM4411X/*.3C(_ FOHWPKH47AOPW9:9$!F)!YA_O.?O'\ZSJ1]G?S*B^>Q\\_
M$_\ Y*+JO^\O_H(KL/@/_P A'6/^N2?SKC_B?_R475O]Y?\ T$5V'P'_ .0C
MK'_7)/YUM/\ @F<?XA[?7EOB#/CCXD6F@1Y;3-)Q/>$=&?LM=MXO\01>&O#5
MWJ4A&]$VQ+_><]!7E7@/Q_X9\,Z7.^H-?2:I>2F:ZD6W)&3T .>E<].+LY)&
MLVKV9K?&?PH+G38=>M(AYEJ!'.%'6/L?PKQ_0-9N/#^N6NJ6Q.^!P6 _B7N/
MRKW"\^,'@R]LYK6X34&AF0HZFUZ@_C7@=X+47TXLG=[7>?*9UVMM[9%=%'FY
M>62,JEKW1]=Z5J5OJ^EVVH6K!H9T#J1[]JN5XG\%?%?E32^&[J3Y7S+:DGO_
M !+_ %KVRN2I!PE8WC+F5SY<^)/_ "4+6/\ KK_2MOX3^)(/#MUJ<D]CJ-T)
M40#[%;F4K@GKCI6)\2?^2A:Q_P!=?Z5VWP''^EZR?]B/^9KLG;V.ISQ_B%SQ
M'\;K86DMMH>GW2W3 KYMVH01'_=R23]<5YYX:\#:YXSF>>U>W$1?,T\LRY4G
MJ2H^;]!7H/QF\'[XE\2V47SIA+M5'4=G_H:\N\+^)+SPKKD.I6C$@';-%GB5
M.X/]*5-+DO3W'-OFM(^E_"7A>T\):%%IMJQD(.Z65A@R.>IJ'Q[_ ,B)K/\
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86RQR>@%;SJ\\+/<SC#EE=&S1116!H?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
